Updates on the pathophysiology and management of acne rosacea

Postgraduate Medicine

Volumn 121, Issue 5, 2009, Pages 178-186

  Elsaie, Mohamed L ^a   Choudhary, Sonal ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Acne rosacea; Erythema; Pustules; Sulfur

Indexed keywords

ATOPICLAIR; AZELAIC ACID; AZITHROMYCIN; BENZOYL PEROXIDE; BENZOYL PEROXIDE PLUS CLINDAMYCIN; CALCINEURIN INHIBITOR; CLARITHROMYCIN; CLINDAMYCIN; CYCLOSPORIN; DERMATOLOGICAL AGENT; DOXYCYCLINE; DUAC; ELETONE; EPICREAM; ERYTHROMYCIN; ISOTRETINOIN; METRONIDAZOLE; MIMYX; MINOCYCLINE; MOISTURIZING AGENT; OXYMETAZOLINE; OXYTETRACYCLINE; PERMETHRIN; PIMECROLIMUS; SULFACET R; SULFACETAMIDE; SULFACETAMIDE PLUS SULFUR; TACROLIMUS; TETRACYCLINE; UNCLASSIFIED DRUG;

DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; ERYTHEMA; HUMAN; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; INNATE IMMUNITY; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MEDICAL DECISION MAKING; PAPULE; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTOTHERAPY; PUSTULE; QUALITY OF LIFE; REVIEW; ROSACEA; SURGICAL TECHNIQUE; SYSTEMIC THERAPY; TASTE DISORDER; TOPICAL TREATMENT; VASCULAR DISEASE;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; HUMANS; ISOTRETINOIN; METRONIDAZOLE; PHOTOTHERAPY; ROSACEA; SULFACETAMIDE;

EID: 75749121637     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.09.2066     Document Type: Review

References (95)

1. Wilkin J, Dahl M, Detmar M, et al; National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the National Rosacea Society Expert Commnittee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907-912.
2. National Rosacea Society. What is rosacea? http://www.rosacea.org. Accessed January 20, 2009.
3. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78(2):97-100.
4. Gupta AK, Gover MD. Azelaic acid (15% gel) in the treatment of acne rosacea. Int J Dermatol. 2007;46(5):533-538. (Pubitemid 46711441)
5. Breathnach AS. Azelaic acid: potential as a general antitumoural agent. Med Hypothesis. 1999;52(3):221-226. (Pubitemid 29199803)
6. van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J Am Acad Dermatol. 2007;56(1):107-115.
7. Liu RH, Smith MK, Basta SA, Farmer ER. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. Arch Dermatol. 2006;142(8):1047-1052. (Pubitemid 44268483)
8. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustule rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48(6):836-845.
9. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139(11):1444-1450. (Pubitemid 37433134)
10. Bikowski JB, Goldman MP. Rosacea: where are we now? J Drugs Dermatol. 2004;3(3):251-261.
11. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40(6 pt 1):961-965.
12. Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7(6):541-546.
13. McClellan KJ, Noble S. Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol. 2000;1(3):191-199.
14. Nally JB, Berson DS. Topical therapies for rosacea. J Drugs Dermatol. 2006;5(1):23-26.
15. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol. 1998;39(3):502-504. (Pubitemid 28417396)
16. van Zuuren EJ, Graber MA, Hollis S, Chaudhry M, Gupta AK, Gover M. Interventions for rosacea. Cochrane Database Syst Rev. 2005;(3):CD003262.
17. Tan JK, Girard C, Krol A, et al. Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. J Cutan Med Surg. 2002;6(6):529-534. (Pubitemid 36091497)
18. Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol. 1983;109(1):63-65.
19. Veien NK, Christiansen JV, Hjorth N, Schmidt H. Topical metronidazole in the treatment of rosacea. Cutis. 1986;38(3):209-210.
20. Sauder DN, Miller R, Gratton D, et al. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet)is demonstrated in a double-blind study. J Dermatolog Treat. 1997;8(2):79-85. (Pubitemid 27338511)
21. Lebwohl M, Medansky RS, Russo CL, et al. The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet-R®) lotion and metronidazole 0.75% (Metrogel®) in the treatment of rosacea. J Geriatr Dermatol. 1995;3(5):183-185.
22. Trumbore MW, Goldstern JA, Gurge RM. Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. J Drugs Dermatol. 2009;8(3):299-304.
23. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51(4):499-512.
24. Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70(5):271-275.
25. Berman B, Zell D. Subantimicrobial dose doxycycline: a unique treatment for rosacea. Cutis. 2005;75( suppl 4):19-24. (Pubitemid 40627621)
26. Theobald K, Bradshaw M, Leyden J. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed. 2007;6(5):221-226.
27. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8(7):639-648.
28. Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet. 1976;1(7971):1211-1212.
29. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol. 1980;102(4):443-445.
30. Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol. 1983;109(1):63-65.
31. Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007;12(2):1-5.
32. Torresani C. Clarithromycin: a new perspective in rosacea treatment. Int J Dermatol. 1998;37(5):347-349. (Pubitemid 28231308)
33. Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol. 1997;36(12):942-946. (Pubitemid 28053900)
34. Korting H, Schöllmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol. 2009;23(8):876-882.
35. Fowler JF Jr. Combined effect of anti-inflammatory dose doxycyclme (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6(6):641-645.
36. Butterwick KJ, Butterwick LS, Han A. Laser and light therapies for acne and rosacea. J Drugs Dermatol. 2006;5(1):35-39.
37. Jørgensen GF, Hedelund L, Haedersdal M. Long-pulsed dye laser versus intense pulsed light for photodamaged skin: a randomized split-face trial with blinded response evaluation. Lasers Surg Med. 2008;40(5):293-299. (Pubitemid 351920378)
38. Bernstein EF, Kligman A. Rosacea treatment using the new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser. Lasers Surg Med. 2008;40(4):233-239. (Pubitemid 351628524)
39. Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol. 2004;51(4):592-299.
40. Larson AA, Goldman MP. Recalcitrant rosacea successfully treated with multiplexed pulsed dye laser. J Drugs Dermatol. 2007;6(8):843-845.
41. Papageorgiou P, Clayton W, Norwood S, Chopra S, Rustin M. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol. 2008;159(3):628-632.
42. Neuhaus IM, Zane LT, Tope WD. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg. 2009;35(6):920-928.
43. Nybaek H, Jemec GB. Photodynamic therapy in the treatment of rosacea. Dermatology. 2005;211(2):135-138.
44. Bryld LE, Jemec GB. Photodynamic therapy in a series of rosacea patients. J Eur Acad Dermatol Venereol. 2007;21(9):1199-1202.
45. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med. 2007;13(7):851-856. (Pubitemid 47038190)
46. Taylor KR, Yamasaki K, Radek KA, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem. 2007;282(25):18265-18275. (Pubitemid 47100227)
47. Shibata M, Katsuyama M, Onodera T, Ehama R, Hosoi J, Tagami H. Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol. 2009;129(2):375-382.
48. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-980. (Pubitemid 47222043)
49. Schauber J, Dorschner RA, Coda AB, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest. 2007;117(3):803-811. (Pubitemid 46348539)
50. De Yang, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1(FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes and, T-cells. J Exp Med. 2000;192(7):1069-1074.
51. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111(11):1665-1672.
52. Gallo RL, Ono M, Povsic T, et al. Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci U S A. 1994;91(23):11035-11039. (Pubitemid 24349620)
53. Buechner SA. Rosacea: an update. Dermatology. 2005;210(2):100-108.
54. Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alphal-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143(11): 1369-1371.
55. Gomaa AH, Yaar M, Eyada MM, Bhawan J. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol. 2007;34(10):748-753.
56. Brauchle M, Funk JO, Kind P, Werner S. Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem. 1996;271(36):21793-21797.
57. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111(11):1665-1672.
58. Tokumaru S, Sayama K, Shirakata Y, et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol. 2005;175(7):4662-4668.
59. Detmar M, Brown LF, Claffey KP, Yeo KT, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994;180(3):1141-1146. (Pubitemid 24256627)
60. Bakar O, Demirçay Z, Yuksel M, Haklar G, Sanisoglu Y. The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol. 2007;32(2):197-200. (Pubitemid 46233028)
61. Jain A, Sangal L, Basal E, Kaushal GP, Agarwal SK. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J. 2002;8(2):2.
62. Young CN, Koepke JI, Terlecky LJ, Borkm MS, Boyd Savoy L, Terlecky SR. Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol. 2008;128(11):2606-2614.
63. Peus D, Vasa RA, Beyerle A, Meves A, Krautmacher C, Pittelkow MR. UVB activates ERK1/2 and p38 signaling pathways via reactive oxygen species in cultured keratinocytes. J Invest Dermatol. 1999;112(5):751-756. (Pubitemid 29220718)
64. 2 is an important mediator of UVB-induced EGF-receptor phosphorylation in cultured keratinocytes. J Invest Dermatol. 1998;110(6):966-971. (Pubitemid 28237706)
65. Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol. 1986;86(4):449-153. (Pubitemid 16050027)
66. Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283(3):162-166.
67. Akamatsu H, Oguchi M, Nishijiina S, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res. 1990;282(7):449-454. (Pubitemid 20350067)
68. Bielenberg DR, Bucana CD, Sanchez R, Donawho CK, Kripke ML, Fidler IJ. Molecular regulation of UVB-induced cutaneous angiogenesis. J Invest Dermatol. 1998;111(5):864-872. (Pubitemid 28509331)
69. Longuet-Perret I, Schmitt D, Viac J. Tumour necrosis factor-alpha is involved in the contrasting effects of ultraviolet B and ultraviolet A1 radiation on the release by normal human keratinocytes of vascular permeability factor. Br J Dermatol. 1998;138(2):221-224. (Pubitemid 28114121)
70. Naru E, Suzuki T, Moriyama M, et al. Functional changes induced by chronic UVA irradiation to cultured human dermal fibroblasts. Br J Dermatol. 2005;153(suppl 2):6-12. (Pubitemid 41784067)
71. Wlaschek M, Briviba K, Stricklin GP, Sies H, Scharffetter-Kochanek K. Singlet oxygen may mediate the ultraviolet A-induced synthesis of interstitial collagenase. J Invest Dermatol. 1995;104(2):194-198.
72. Caubet C, Jonca N, Brattsand M, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol. 2004;122(5):1235-1244. (Pubitemid 38651099)
73. Descargues P, Deraison C, Prost C, et al. Corneodesmosomal Cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol. 2006;126(7):1622-1632. (Pubitemid 43910379)
74. Michael IP, Sotiropoulou G, Pampalakis G, et al. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem. 2005;280(15):14628- 14635. (Pubitemid 40562808)
75. Kawaguchi Y, Tanaki H, Okada T, et al. The effects of ultraviolet A and reactive oxygen species on the in RNA expression of 72-kDa type IV collagenase and its tissue inhibitor in cultured human dermal fibroblasts. Arch Dermatol Res. 1996;288(1):39-44. (Pubitemid 26009224)
76. Lee Y, Kim H, Kim S, et al. Myeloid differentiation factor 88 regulates basal and UV-induced expressions of IL-6 and MMP-1 in human epidermal keratinocytes. J Invest Dermatol. 2009;129(2):460-467.
77. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258-265. (Pubitemid 43144395)
78. Sorsa T, Lindy O, Konttinen YT, Suomalainen K, et al. Doxycycline in the protection of serum alpha-1-antitrypsin from human neutrophil collagenase and gelatinase. Antimicrob Agents Chemother. 1993;37(3):592-594. (Pubitemid 23072607)
79. Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol. 2007;157(3):474-481. (Pubitemid 47256121)
80. Erbaǧci Z, Ozgöztaşi O. The significance of Demodex folliculorum density in rosacea. Int J Dermatol. 1998;37(6):421-425. (Pubitemid 28284868)
81. Costa CP, Kirschning CJ, Busch D. Role of chlamydial heat shock protein 60 in the stimulation of innate immune cells by Chlamydia pneumoniae. Eur J Immunol. 2002;32(9):2460-2470.
82. Gobert AP, Bambou JC, Werts C, et al. Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism. J Biol Chem. 2004;279(1):245-250. (Pubitemid 38044821)
83. Gürer MA, Erel A, Erbaǧ D, Caşlar K, Atahan C. The seroprevalence of Helicobacter pylori and nitric oxide in acne rosacea. Int J Dermatol. 2002;41(11):768-770. (Pubitemid 35422841)
84. Baz K, Cimen MY, Kokturk A, et al. Plasma reactive oxygen species activity and antioxidant potential levels in rosacea patients: correlation with seropositivity to Helicobacter pylori. Int J Dermatol. 2004;43(7):494-497. (Pubitemid 39023033)
85. Kawahara T, Kuwano Y, Teshima-Kondo S, et al. Toll-like receptor 4 regulates gastric pit cell responses to Helicobacter pylori infection. J Med Invest. 2001;48(3-4):190-197.
86. Smith MF Jr, Mitchell A, Li G, et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kippa B activation and chemokine expression by epithelial cells. J Biol Chem. 2003;278(35):325552-32560. (Pubitemid 37055693)
87. Draelos ZD, Ertel K, Berge C. Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. Cutis. 2005;76(2):135-141. (Pubitemid 41290900)
88. Breneman D, Savin R, VandePol C, Vamvakias G, Levy S, Leyden J. Double-blind, randomized, vehicle-control led clinical trial of once-daily benzoyl peroxide clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43(5):381-387. (Pubitemid 38714606)
89. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001;44(6):995-998. (Pubitemid 32493451)
90. Mostafa FF, El Harras MA, Gomaa SM, Al Mokadem S, Nassar AA, Abdel Gawad EH. Comparative study of some treatment modalities of rosacea. J Eur Acad Dermatol Venereol. 2009;23(1):22-28.
91. Karincaoglu Y, Bayram N, Aycan O, Esrefoglu M. The clinical importance of demodex folliculorum presenting with nonspecific facial signs and symptoms. J Dermatol. 2004;31(8):618-626. (Pubitemid 39243784)
92. Dahl MV, Jarratt M, Kaplan D, Tuley MR, Baker MD. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45(5):723-730. (Pubitemid 33032570)
93. Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143(11):1369-1371.
94. Shanler S, Ondo A. Successful treatment of the erythema and flushing of rosacea using a topically applied selective 1-adrenergic receptor agonist, oxyinetazoline (Abstract). J Am Acad Dermatol. 2008;58(2):AB9.
95. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyelosporine for the treatment of ocular rosacea. Adv Ther. 2009;26(6):651-659.